UBS Group’s Neos Therapeutics, Inc NEOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-11,916
| Closed | -$7K | – | 9861 |
|
|
2020
Q4 | $7K | Buy |
+11,916
| New | +$7.36K | ﹤0.01% | 7738 |
|
|
2020
Q3 | – | Sell |
-26,555
| Closed | -$18K | – | 8694 |
|
|
2020
Q2 | $18K | Buy |
26,555
+18,839
| +244% | +$14.9K | ﹤0.01% | 6640 |
|
|
2020
Q1 | $6K | Buy |
7,716
+2,669
| +53% | +$3.67K | ﹤0.01% | 7262 |
|
|
2019
Q4 | $8K | Buy |
5,047
+3,045
| +152% | +$4.57K | ﹤0.01% | 7418 |
|
|
2019
Q3 | $3K | Buy |
2,002
+1,750
| +694% | +$2.83K | ﹤0.01% | 7694 |
|
|
2019
Q2 | $0 | Sell |
252
-17,881
| -99% | -$32.9K | ﹤0.01% | 8338 |
|
|
2019
Q1 | $47K | Buy |
18,133
+1,263
| +7% | +$2.96K | ﹤0.01% | 5599 |
|
|
2018
Q4 | $27K | Buy |
16,870
+15,005
| +805% | +$42.1K | ﹤0.01% | 6575 |
|
|
2018
Q3 | $9K | Sell |
1,865
-59,942
| -97% | -$340K | ﹤0.01% | 7233 |
|
|
2018
Q2 | $386K | Sell |
61,807
-6,170
| -9% | -$46K | ﹤0.01% | 4504 |
|
|
2018
Q1 | $564K | Sell |
67,977
-857
| -1% | -$8.18K | ﹤0.01% | 4125 |
|
|
2017
Q4 | $702K | Sell |
68,834
-1,628
| -2% | -$15.6K | ﹤0.01% | 4045 |
|
|
2017
Q3 | $645K | Sell |
70,462
-174,516
| -71% | -$1.33M | ﹤0.01% | 4029 |
|
|
2017
Q2 | $1.79M | Buy |
244,978
+136,264
| +125% | +$1.03M | ﹤0.01% | 3123 |
|
|
2017
Q1 | $783K | Buy |
108,714
+6,276
| +6% | +$38.9K | ﹤0.01% | 3725 |
|
|
2016
Q4 | $599K | Buy |
102,438
+34,279
| +50% | +$232K | ﹤0.01% | 3976 |
|
|
2016
Q3 | $448K | Buy |
68,159
+61,420
| +911% | +$487K | ﹤0.01% | 3984 |
|
|
2016
Q2 | $63K | Buy |
6,739
+1,761
| +35% | +$16.8K | ﹤0.01% | 5349 |
|
|
2016
Q1 | $54K | Buy |
4,978
+1,417
| +40% | +$14.9K | ﹤0.01% | 5448 |
|
|
2015
Q4 | $51K | Sell |
3,561
-760
| -18% | -$11.5K | ﹤0.01% | 5800 |
|
|
2015
Q3 | $91K | Buy |
+4,321
| New | +$95.2K | ﹤0.01% | 5313 |
|
UBS Group's NEOS Position: Q1 2021 in Review
UBS Group sold out of Neos Therapeutics, Inc (NEOS) in Q1 2021, closing a stake of 11,916 shares — an estimated $7K sold.
UBS Group first reported a position in NEOS in Q3 2015 and held it in 21 quarters. The position peaked at $1.79M in Q2 2017. 0 funds tracked by Wall St. Rank hold NEOS as of Q1 2021.
- UBS Group reported no remaining Neos Therapeutics, Inc position as of Q1 2021 after selling out during the quarter.
- UBS Group sold 11,916 Neos Therapeutics, Inc shares in Q1 2021, an estimated $7K.
- UBS Group first reported a position in Neos Therapeutics, Inc in Q3 2015 and held it in 21 quarters.
- UBS Group's Neos Therapeutics, Inc position peaked at $1.79M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q1 2021.
Based on UBS Group's 13F filing for Q1 2021, filed 12 May 2021.